Can a 'Baby Dose' of hormone drugs prevent breast cancer with fewer side effects?
NCT ID NCT06364267
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two low-dose hormone drugs, exemestane and tamoxifen, in 140 postmenopausal women at high risk for breast cancer. The goal is to see which one better maintains quality of life over 12 months while helping prevent cancer. Participants take a daily pill and complete questionnaires about their symptoms and well-being.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
E.O. Ospedali Galliera
RECRUITINGGenova, Italy, 16128, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?